阿斯利康完成$7亿收购阿特维斯品牌呼吸业务

2015年3月3日讯/生物谷BIOON/--阿斯利康（AZN）今日宣布，已完成对阿特维斯位于美国及加拿大品牌呼吸系统业务的收购。该笔交易耗资7亿美元，包括一笔6亿美元的付款及1亿美元的额外付款。通过此次收购，阿斯利康获得了阿特维斯2种慢性阻塞性肺病（COPD）药物（TudorzaPressair及Daliresp在美国和加拿大的商业化权利及另一种实验性COPD药物的研发和商业化权利。值得一提的是，Daliresp是慢性阻塞性肺病（COPD）市场首个也是唯一一个选择性磷酸二酯酶-4抑制剂。
正如此前所披露的，该笔战略性交易建立于阿斯利康2014年21亿美金收购Almirall呼吸系统业务的基础之上。这2笔交易，将大大增强阿斯利康在全球范围内的呼吸系统特许经营权。收购Almirall获得的呼吸系统资产包括：Eklira（aclidinium，阿地尼亚）、LAS40464（阿地尼亚+福莫特罗复方药，已获欧盟批准品牌名DuaklirGenuair，在美国处于在研）、LAS100977（abediterol，一种每日一次的长效β2受体激动剂LABA，处于II期临床）、处于临床前开发（LAS191351，LAS194871）和I期临床（LAS190792）的M3拮抗剂β2受体激动剂（MABA）平台、多个临床前项目。
此次交易收购的资产包括：TudorzaPressair（阿地溴铵吸入性粉剂），一种抗胆碱能药物，适用于慢性阻塞性肺病（COPD）相关支气管痉挛（肺气道变窄）的长期维持治疗，包括慢性支气管炎和肺气肿；Daliresp（roflumilast，罗氟司特)，是FDA批准的首个也是唯一一种选择性磷酸二酯酶-4(PDE-4)抑制剂，适用于严重慢性阻塞性肺病（COPD）患者降低急性发作风险，不适用于急性支气管痉挛的缓解。
呼吸系统专营权是阿斯利康的主要增长平台之一，也是其重点发展的领域之一；通过外部收购并结合自身的创新能力，阿斯利康意在加强哮喘和慢性阻塞性肺病（COPD）整个护理范畴的应对能力。
英文原文：AstraZenecacompletesacquisitionofrightstoActavis’brandedrespiratoryportfoliointheUSandCanada
Tuesday,3March2015
AstraZenecatodayannouncedthatithascompletedthetransactiontoacquiretherightstoActavis’brandedrespiratorybusinessintheUSandCanada.
Aspreviouslyannounced,thestrategictransactionstrengthensAstraZeneca’srespiratoryfranchisegloballyandbuildsontheacquisitionofAlmirall’srespiratoryportfolioin2014byextendingthecompany’sdevelopmentandcommercialisationrightsintotheUSforbothTudorzaPressairandDuaklirGenuair.
AstraZenecaownsthedevelopmentandcommercialrightsintheUSandCanadatoTudorzaTMPressairTM(aclidiniumbromideinhalationpowder),atwice-dailylong-actingmuscarinicantagonist(LAMA)forchronicobstructivepulmonarydisease(COPD),andtoDaliresp®(roflumilast),theonlyonce-dailyoralPDE4inhibitorcurrentlyonthemarketforCOPD,intheUS.AstraZenecaalsoownsthedevelopmentrightsintheUSandCanadaforLAS40464,thecombinationofafixeddoseofaclidiniumwithformoterollongactingbetaagonist(LAMA/LABA)inadrypowderinhaler,whichisapprovedintheEUunderthebrandnameDuaklir®Genuair®.
Oncompletionoftheacquisition,AstraZenecaispayingActavis$600millionofinitialconsiderationandagreedtopaylowsingle-digitroyaltiesaboveacertainrevenuethreshold.AstraZenecahasalsopaidActavisanadditional$100millionforanumberofcontractualconsentsandapprovals,includingcertainamendmentstotheongoingcollaborationagreementsbetweenAstraZenecaandActavis.
NOTESTOEDITORS
AboutTudorzaPressair
TudorzaPressair(aclidiniumbromideinhalationpowder)400mcgisananticholinergicindicatedforthelong-termmaintenancetreatmentofbronchospasmassociatedwithchronicobstructivepulmonarydisease(COPD),includingchronicbronchitisandemphysema.Whengivenbyinhalation,aclidiniumproducesbronchodilationbyinhibitingthemuscarinicM3receptorintheairwaysmoothmuscle.Aclidiniumisrapidlyhydrolyzedinhumanplasmaintotwomajorinactivemetabolites.
Tudorzaisadministeredusingamultiple-dosedrypowderinhaler,Pressair,whichdelivers60dosesofaclidiniumbromidepowderforinhalation.ThePressairinhalerhasacoloredcontrolwindowandaudible“click”whichconfirmsuccessfulinhalationofthedoseandadoseindicatortoletpatientsknowhowmanydosesremainintheinhaler.
AboutDaliresp
Daliresp(500mcg)isaselectivePDE4inhibitorthatisindicatedasatreatmenttoreducetheriskofexacerbationsinpatientswithsevereCOPDassociatedwithchronicbronchitisandahistoryofexacerbations.Dalirespisaonce-dailyoraltabletandisthefirstandonlyselectivePDE4inhibitorapprovedbytheFDA.
WhilethespecificmechanismbywhichDalirespexertsitstherapeuticactioninCOPDpatientsisnotwelldefined,itisthoughttoberelatedtotheeffectsofincreasedintracellularcyclicAMPinthelungcells.Dalirespisnotasteroid,isnotabronchodilatorandisnotindicatedforthereliefofacutebronchospasm.
AboutCOPD
COPD(chronicobstructivepulmonarydisease)isaprogressivediseaseassociatedmainlywithtobaccosmoking,airpollutionoroccupationalexposure,whichcancauseobstructionofairflowinthelungsresultingindebilitatingboutsofbreathlessness.Itaffectsanestimated300millionpeopleworldwideandispredictedtobethethirdleadingcauseofdeathby2020.AlthoughCOPDiswidelyregardedasadiseaseoftheelderly,50percentofpatientsareestimatedtobebetween50and65yearsofage,meaninghalfoftheCOPDpopulationislikelytobeaffectedatastageintheirlifewhentheyareatthepeakoftheirearningpotentialandarelikelytohavemajorfamilyresponsibilities.
医药网新闻